20 mg- White cap and white body, size “4” hard gelatin capsule imprinted with “W991” in black ink on body, filled with white to pink color powder.
40 mg- Blue cap and white body, size “3” hard gelatin capsule imprinted with “W992” in black ink on body, filled with white to pink color powder.
60 mg- Pink cap and white body, size “2” hard gelatin capsule imprinted with “W993” in black ink on body, filled with white to pink color powder.
80 mg- Blue cap and blue body, size “1” hard gelatin capsule imprinted with “W994” in black ink on body, filled with white to pink color powder.
They are supplied in the following strengths and package configurations:
|Ziprasidone Hydrochloride Capsules|
|Package Configuration||Capsule Strength (mg)||NDC Code||Imprint|
|Bottles of 30||20||NDC-64679-991-01||991|
|Bottles of 60||20||NDC-64679-991-02||991|
|Bottles of 100||20||NDC-64679-991-03||991|
|Bottles of 500||20||NDC-64679-991-04||991|
|Carton of 80 (10 cards containing 8 Capsules each) Capsules||20||NDC-64679-991-06||991|
|Bottles of 30||40||NDC-64679-992-01||992|
|Bottles of 60||40||NDC-64679-992-02||992|
|Bottles of 100||40||NDC-64679-992-03||992|
|Bottles of 500||40||NDC-64679-992-04||992|
|Carton of 80 (10 cards containing 8 Capsules each) Capsules||40||NDC-64679-992-06||992|
|Bottles of 30||60||NDC-64679-993-01||993|
|Bottles of 60||60||NDC-64679-993-02||993|
|Bottles of 100||60||NDC-64679-993-03||993|
|Bottles of 500||60||NDC-64679-993-04||993|
|Carton of 80 (10 cards containing 8 Capsules each) Capsules||60||NDC-64679-993-06||993|
|Bottles of 30||80||NDC-64679-994-01||994|
|Bottles of 60||80||NDC-64679-994-02||994|
|Bottles of 100||80||NDC-64679-994-03||994|
|Bottles of 500||80||NDC-64679-994-04||994|
|Carton of 80 (10 cards containing 8 Capsules each) Capsules||80||NDC-64679-994-06||994|
See FDA Approved Patient Labeling (17.4).
Please refer to the patient package insert. To assure safe and effective use of ziprasidone hydrochloride capsules, the information and instructions provided in the patient information should be discussed with patients.
Patients should be instructed to take ziprasidone hydrochloride capsules with food for optimal absorption. The absorption of ziprasidone is increased up to two-fold in the presence of food [see Drug Interactions (7.8) and Clinical Pharmacology (12.3)].
Patients should be advised to inform their health care providers of the following: History of QT prolongation; recent acute myocardial infarction; uncompensated heart failure; prescription of other drugs that have demonstrated QT prolongation; risk for significant electrolyte abnormalities; and history of cardiac arrhythmia [see Contraindications (4.1) and Warnings and Precautions (5.2)].
Patients should be instructed to report the onset of any conditions that put them at risk for significant electrolyte disturbances, hypokalemia in particular, including but not limited to the initiation of diuretic therapy or prolonged diarrhea. In addition, patients should be instructed to report symptoms such as dizziness, palpitations, or syncope to the prescriber [see Warnings and Precautions (5.2) ].
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.